Drugs Made In America Acquisition (DMII) Equity Ratio (2024 - 2025)

Drugs Made In America Acquisition (DMII) reported Equity Ratio of 0.04 for Q4 2025, up 95.84% year-over-year from 0.02 in Q4 2024, and down 2.05% on a QoQ basis from 0.03 in Q3 2025.

Drugs Made In America Acquisition (DMII) has 2 years of Equity Ratio data on file, last reported at 0.04 in Q4 2025.

  • Quarterly Equity Ratio rose 95.84% year-over-year to 0.04 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.04 (up 95.84% YoY) and the FY2025 annual result came in at 0.04, up 95.84% from the prior year.
  • Equity Ratio fell to 0.04 in Q4 2025 per DMII's latest filing, from 0.03 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.03 in Q3 2025 and bottomed at 0.85 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Ratio (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - -0.03
2 Berto Acquisition 316.66 Mn 316.66 Mn - -0.04
3 Centurion Acquisition 311.94 Mn 311.94 Mn - -0.04
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn - -0.04
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn - -0.08
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn - -0.06
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn - -0.03
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn - -0.05
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn - -0.03
10 Drugs Made In America Acquisition 128.97 Mn 128.97 Mn - -0.04

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -0.04
Sep 30, 2025 -0.03
Dec 31, 2024 -0.85